Health Professional Radio - Podcast

Dr. Matthew Smith, MD, Professor of Medicine at Harvard Medical School and Director of the Genitourinary Malignancies Program at Massachusetts General Hospital Cancer Center discusses final data published in the "New England Journal of Medicine" (Sep 2020) from the Phase III ARAMIS trial for NUBEQA® (darolutamide) plus androgen deprivation therapy in men with non-metastatic castration-resistant prostate cancer (nmCRPC).